25 results about "NS3" patented technology

This invention discloses a primer set for amplifying a novel HCV subtype 6xp and a primer set for detecting drug resistance mutations. The primer set for amplifying the novel HCV subtype 6xp includes nested PCR primers for amplifying the full length of the novel HCV subtype 6xp, while the primer set for detecting drug resistance mutations is a set of primers targeting drug resistance mutation sites in the three functional regions of NS3, NS5A, and NS5B. The primer set provided by this invention has high specificity and high amplification efficiency, enabling specific amplification of the entire genome of the novel HCV subtype 6xp and accurate detection of drug resistance mutation sites in the three functional regions. It is suitable for clinical diagnosis, antiviral treatment guidance, epidemiological surveys, and viral evolution research of this subtype, and has significant clinical application value and scientific research significance.

The invention discloses an HCV recombinant fusion antigen protein which comprises a Core antigen epitope, an NS3 antigen epitope region and an NS5A antigen epitope of HCV which are connected in series, the amino acid sequence of the Core antigen epitope is as shown in SEQ ID NO: 1, the amino acid sequence of the NS3 antigen epitope is as shown in SEQ ID NO: 2, and the amino acid sequence of the NS5A antigen epitope is as shown in SEQ ID NO: 3. The HCV recombinant fusion antigen protein obtained by the invention has relatively high detection rate and specificity.

This invention belongs to the field of biomedical technology, specifically relating to a drug control system based on the KFERQ sequence, its construction method, and its application. This drug control system is composed of a KFERQ sequence, an HCV-NS3 sequence, and a protein-targeting sequence recombined together. During recombination, the protein-targeting sequence is located at the N-terminus or C-terminus of the recombinant sequence. This invention provides a novel strategy for endogenous protein degradation by recombinating the KFERQ sequence with the HCV-NS3 sequence and the endogenous protein-targeting sequence, and utilizing the self-cleavage property of the HCV-NS3 protease to regulate the degradation of endogenous proteins.

The invention belongs to the technical field of animal pathogen molecular biology, and particularly relates to a dual quantitative fluorescent primer probe composition, a kit and an identification method for identifying hog cholera virus. Aiming at the current popular strains covering 3 genotypes, 11 gene subtypes and the like of the hog cholera gene, the invention selects 5UTR and NS3 gene sequences of hog cholera virus to design and synthesize specific primers and probes aiming at the two fragments; the specific primer has no non-specific amplification on African swine fever virus, pseudorabies virus, porcine reproductive and respiratory syndrome virus, porcine circovirus type II, porcine epidemic diarrhea and bovine viral diarrhea. The invention establishes a method for identifying the classical swine fever virus wild strain and the vaccine strain and develops a kit convenient for diagnosis, and the kit and the identification method can simultaneously identify the classical swine fever virus wild strain and the vaccine strain, have the characteristics of high sensitivity, strong specificity, good repeatability and good stability, and have extremely strong application prospects.

The invention provides a hybridoma cell strain secreting an anti-bovine viral diarrhea virus NS3 protein monoclonal antibody and application of the hybridoma cell strain, and belongs to the technical field of biology. The preservation number of the hybridoma cell strain 4B3 is CCTCC (China Center For Type Culture Collection) NO: C2025217. The invention also provides an anti-bovine viral diarrhea virus NS3 protein monoclonal antibody secreted by the hybridoma cell strain 4B3 and a sandwich ELISA kit for detecting bovine viral diarrhea virus. The hybridoma cell strain 4B3 obtained through screening can be specifically combined with recombinant NS3 protein and NS3 protein in cells infected with BVDV-1 and BVDV-2 type strains, so that the BVDV-1 and BVDV-2 type strains can be detected with high sensitivity and high specificity, and the hybridoma cell strain 4B3 can be used for Western blot detection and immunofluorescence detection of BVDV.

A method for the extraction and enrichment of Hepatitis C Virus (HCV) antigens by conjugating specific antibodies targeting Envelope 1, Envelope 2, NS3, and NS4 antigens to a temperature-responsive smart polymer (NIPAAm-Co-HIPAAm-Co-SAKIPAAm). The application also relates to a detection kit for HCV antigens, comprising the smart polymer conjugated to specific antibodies, colloidal gold nanoparticles conjugated to specific antibodies, and instructions for detecting HCV antigens in serum, plasma, or whole blood samples.

The present invention pertains to compounds that inhibit Flavivirus NS2B-NS3 proteases and are potent and selective inhibitors of the West Nile virus and Zika virus. The compounds of the invention can be used alone or in combination with other agents to treat infections caused by these viruses. Additionally, the invention relates to pharmaceutical compositions containing these compounds.

The application provides a hepatitis C antibody detection antigen composition and application, kit and detection method thereof, relates to the antibody detection technical field, and the hepatitis C antibody detection antigen composition comprises a labeled recombinant antigen and a coated recombinant antigen, the amino acid sequence of the labeled recombinant antigen includes Trx and hepatitis C Core region, NS3 protein, NS4b protein dominant epitope and His tag, and the full-length sequence is shown as SEQ ID NO. 1. The labeled recombinant antigen used in the application is obtained by mutating 7 cysteines (C) into alanine (A) by amino acid mutation on the NS3 protein, reducing the aggregation and precipitation caused by disulfide bond of the recombinant protein, and improving the protein stability. When colloidal gold is used for antigen labeling, a secondary indirect labeling method is adopted, which is beneficial to the exposure of antigen epitopes, can improve the reaction sensitivity, and reduces the antibody missed detection.

Provided herein are compositions and methods that allow for controlled interaction between a target protein and a polypeptide to which a binding protein is fused. Compositions and methods utilize a target protein that binds to the hepatitis C virus protease inhibitor glaprevir to form a complex, and a Tn3 binding protein that specifically binds to the complex. The target protein is or is derived from a viral protease, such as an HCV NS3 / 4A protease.

The application provides application of zinc pyrithione in preparation of a medicine for treating Japanese encephalitis virus infection. The application has the beneficial effect that the zinc pyrithione has significant inhibitory effect on NS2B-NS3 protease activity in the Japanese encephalitis virus, can be used as an inhibitor of the NS2B-NS3 protease in the Japanese encephalitis virus, and is expected to become a potential medicine for resisting Japanese encephalitis virus infection.

The invention relates to compounds that are inhibitors of Flavivirus NS2B-NS3 proteases and inhibit replication of flavivirus in cells. Compounds of this invention are useful alone or in combination with other agents for use in the treatment of infections caused by Flaviviruses, in particular by Dengue, West Nile, Zika, Japan Encephalitis viruses.

The invention provides a hepatitis C antibody detection antigen composition and application thereof, a kit and a detection method, and relates to the technical field of antibody detection, the hepatitis C antibody detection antigen composition comprises a recombinant antigen for marking and a recombinant antigen for coating, the amino acid sequence of the recombinant antigen for marking comprises Trx and hepatitis C Core regions, NS3 protein, NS4b protein dominant epitopes and a His tag, and the full-length sequence is as shown in SEQ ID NO. 1. According to the recombinant antigen for marking, the NS3 protein is subjected to amino acid mutation to mutate seven cysteines (C) into alanine (A), aggregation and precipitation caused by disulfide bonds of the recombinant protein are reduced, and the protein stability is improved. When colloidal gold is labeled by the antigen, a secondary indirect labeling method is adopted, so that the exposure of antigen epitopes is facilitated, the reaction sensitivity can be improved, and the leakage detection of antibodies is reduced.

The application provides application of embelin in preparation of a medicine for resisting St. Louis encephalitis virus infection. The application has the beneficial effect that the embelin has significant inhibitory effect on NS2B-NS3 protease activity in the St. Louis encephalitis virus, can be used as an inhibitor of the NS2B-NS3 protease in the St. Louis encephalitis virus, and is expected to become a potential medicine for resisting St. Louis encephalitis virus infection.

Disclosed are bifunctional compounds (degraders) that target hepatitis C virus (HCV) NS3 / 4A for degradation. Also disclosed are pharmaceutical compositions containing the degraders and methods of using the compounds to treat HCV infection and HCV-associated diseases or disorders.

The invention provides a human hepatitis C virus protein sequence and application thereof, the human hepatitis C virus protein sequence comprises protein fragments C-1, NS3-b and NS5-a with good specificity, high activity and strong stability, and the human hepatitis C virus protein sequence can be used for preparing a product for detecting an HCV antibody. Meanwhile, the invention relates to an antibody detection kit which is simple to operate, does not need a complex process and professional equipment, and can be quickly operated by ordinary personnel; the detection reaction is rapid, the sensitivity is high (trace antibody signals can be captured), the specificity is strong (misdiagnosis and missed diagnosis are reduced), the kit is suitable for on-site rapid detection, and a professional laboratory environment is not needed. The kit is economical in cost and high in cost performance, high-risk populations such as suspected cases, asymptomatic infected persons and carriers can be rapidly screened in the virus epidemic period, and efficient support is provided for epidemic situation prevention and control.

The invention discloses a recombinant humanized anti-HCV NS3 monoclonal antibody, which comprises a light chain and a heavy chain, the monoclonal antibody is named as R-Anti-HCV-NS3-Ab, the amino acid sequence of the light chain is shown as SEQ ID NO.6, the amino acid sequence of the heavy chain is shown as SEQ ID NO.7, and the amino acid sequence of the heavy chain is shown as SEQ ID NO.8. And the amino acid sequence of the heavy chain is as shown in SEQ ID NO.7. The recombinant humanized anti-HCV NS3 monoclonal antibody developed by the patent is designed based on an NS3 conserved epitope region, high affinity to main epidemic subtypes such as 1a, 1b, 2a, 3a, 4a and the like is ensured, and the broad-spectrum detection capability is ensured; through humanized transformation, anti-mouse antibody interference is reduced, false positive is avoided, and reagent stability is improved; multiple platforms such as chemiluminescence and ELISA are adapted; standardized production: a mammalian cell expression system is adopted, and the batch-to-batch consistency is obviously superior to that of a traditional polyclonal antibody; the quality control product disclosed by the invention can be used for accurately evaluating the sensitivity of an HCV antibody detection reagent, and is particularly suitable for regions with complicated genotypes.

This invention relates to a vaccine comprising live attenuated Zika virus comprising a partly codon deoptimized viral genome, a Zika virus comprising a partly codon deoptimized viral genome, as well as their use in methods of treatment and prevention of viral infection. is deoptimized along the nonstructural ZIKV coding region. In some embodiments, the non-structural region of the viral genome is codon deoptimized, and preferably one or more of the genes NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5 are codon deoptimized.

The invention discloses an HDAC8 gene knockout MDBK cell line as well as a construction method and application thereof. According to the method, a CRISPR / Cas9 technology is utilized, specific gRNA is designed aiming at a second exon of a cattle HDAC8 gene, CRISPR expression plasmids are constructed, adherent MDBK cells are transfected, and HDAC8 homozygous frame-shift mutant cell lines KOHDAC8-1 (4bp deletion) and KOHDAC8-2 (1bp insertion) are obtained through puromycin screening and monoclonal separation. An identification result shows that HDAC8 knockout obviously promotes replication of the bovine viral diarrhea virus (BVDV), the expression level of NS3 mRNA and protein of the virus is increased, the virus titer is obviously improved, and the cell growth rate is not obviously influenced. The cell line provided by the invention can be used as an efficient proliferation matrix of the BVDV, is used for producing inactivated vaccines for bovine viral diarrhea, and effectively improves the yield and quality of the vaccines.

The application belongs to the field of genetic engineering, and particularly relates to a construction method and application of a red fluorescent protein labeled recombinant blue tongue virus. The application inserts a red fluorescent protein label sequence (mScarlet3) between 158th and 159th amino acids of a wild type blue tongue virus NS3 protein, and obtains a NS3 labeled recombinant blue tongue virus BTV-1 / NS3-158mScarlet3. Compared with the wild type blue tongue virus, the recombinant NS3 protein can correctly express the red fluorescent protein, but does not affect the replication of the virus, and can be used for expression positioning and dynamic tracking of the NS3 protein in the BTV infected cell, interaction between the NS3 protein and the host protein, BTV neutralization test, antiviral drug screening and gene delivery and the like.

The application provides application of zinc undecylenate in preparation of a drug for resisting dengue virus, and uses zinc undecylenate as an inhibitor of NS2B-NS3 protease in the dengue virus, wherein the zinc undecylenate has good inhibitory activity on the NS2B-NS3 protease in the dengue virus, and the zinc undecylenate has various carriers and administration modes, is convenient to use, and is easy to obtain.

This invention discloses a method for screening drugs against Japanese encephalitis virus, which uses the main protease NS3 of Japanese encephalitis virus. pro The activity reporter plasmid and the main protease NS3 of Japanese encephalitis virus pro Expression plasmids were used to screen for drugs against Japanese encephalitis virus; NS3 pro Active reporter plasmids and NS3 pro The expression plasmid was co-transfected into HEK-293T cells. The fluorescence intensity of green fluorescent protein (EGFP) was detected using an inverted fluorescence microscope and a multi-functional microplate reader to predict NS3. pro The activity of NS3, the main protease of JEV, can be used to screen for its activity. pro The purpose of this invention is to screen anti-JEV compounds using active reporter plasmids. The inhibitory effect of the compounds can be observed more intuitively and easily by utilizing fluorescence intensity, providing a powerful tool for screening broad-spectrum anti-JEV compounds.

The application provides application of hypericin in preparation of a medicine for resisting St. Louis encephalitis virus infection. The application has the beneficial effect that the hypericin has a significant inhibitory effect on NS2B-NS3 protease activity in the St. Louis encephalitis virus, can be used as an inhibitor of the NS2B-NS3 protease in the St. Louis encephalitis virus, and is expected to become a potential medicine for resisting St. Louis encephalitis virus infection.

The invention provides novel classes of HCV therapeutics that are orally available, safe and effective HCV NS3 / 4A protease inhibitors and are less susceptible to drug resistance than existing therapeutics. The invention also relates to pharmaceutical composition of these compounds and methods of preparation and use thereof.